Fundraising Fox
Humacyte
NASDAQ: HUMAMorrisville, US · Delaware corporation · 3 known investors
Find your way into Humacyte
Each arrow is one introduction. Sign up to fill in the first one.
378 people can intro you to Laura
Ask Robert Weisskoff to introduce you to Laura Niklason, MD, PhD
You →Robert · together at Massachusetts General Hospital →Laura
193 people can intro you to Ted
Ask Jamie Chen to introduce you to Ted Lithgow
You →Jamie · together at Schering →Ted
17 people can intro you to Paul
Ask Sam Okafor to introduce you to Paul Boyer
You →Sam · together at Elo Life →Paul
- Dale A Sander13 people can intro you
Sign up to find every way you can get introduced to Humacyte
- Your email: who you already know at Humacyte, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Humacyte team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform. Its off-the-shelf vessels target vascular trauma, AV access, and peripheral artery disease (PAD), and have received FDA Regenerative Medicine Advanced Therapy designation.
Founders & leadership
LN
Laura Niklason, MD, PhDFounderFounder of Humacyte, a regenerative medicine company developing a bioengineered human-derived Acellular Tissue Engineered Vessel and a scalable cell sourcing and manufacturing platform for vascular trauma, AV access, and peripheral artery disease.
TL
Ted LithgowChief Commercial Officer2019–2019Ted Lithgow is an executive in the pharma and biotech sector with background in drug development, medical devices, regulatory affairs, and biotechnology operations. He leads Humacyte, a regenerative medicine company developing bioengineered vascular tissue products.
PB
Paul BoyerChief Financial Officer (CFO)2010–2018His background includes leading an IPO, raising over $1.2B in equity and debt financing, executing 17 M&A transactions, and scaling operations across food ingredients, insurtech, biotech, and consumer retail sectors to revenues exceeding $1B.
CS
Carrie S. CoxExecutive
DA
Dale A. SanderChief Financial Officer and Chief Corporate Development OfficerDale A. Sander has served as Chief Financial Officer at six life science and business service companies across private and public phases, leading financial and operational functions including corporate development, M&A, and strategic planning across multiple continents. His background includes experience managing public offerings, investor relations, and business transitions ranging from startups to global operations with 60,000 employees.
LE
Laura E. NiklasonFounder
Board
RA
Robert AndersonBoard director
RL
Robert LangerBoard director
BW
Brady W. DouganBoard director
MW
Max WallaceBoard director
Investors · 3
First In Ventureslisted by First In VenturesMiddletown · $50K – $200K
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$274.8M disclosed across 3 of 4 rounds · 2007–2026
▶$150MraisedJun 2018 · 1 investors · BiotechnologyRule 506(b)
▶$150MraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey H. LawsonExecutive Officer
- Paul A. BoyerExecutive Officer
- Theodore D. LithgowExecutive Officer
- Robert S. LangerDirector
- Dale A. SanderDirector
- Robert AndersonDirector
- Carrie S. CoxExecutive Officer, Director
- William TenteExecutive Officer
- Brady W. DouganDirector
- Kathleen SebeliusDirector
- Laura E. NiklasonDirector
- Max N. WallaceDirector
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$75MraisedMar 2018 · 29 investors · BiotechnologyRule 506(b)
▶$75MraisedMar 2018 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Carrie S. CoxExecutive Officer, Director
- Max WallaceDirector
- Paul BoyerExecutive Officer
- Laura NiklasonDirector
- Brady W. DouganDirector
- Robert AndersonDirector
- Theodore LithgowExecutive Officer
- Kathleen SebeliusDirector
- Dale A. SanderDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$49.8MraisedJan 2015 · 6 investors · BiotechnologyRule 506(b)
▶$49.8MraisedJan 2015 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert AndersonDirector
- Robert LangerDirector
- Ted LithgowExecutive Officer
- Laura E. NiklasonDirector
- Brady W. DouganDirector
- Max WallaceDirector
- Paul A. BoyerExecutive Officer
- Carrie S. CoxExecutive Officer, Director
- Offering amount
- $73.8M
- Amount sold
- $49.8M
- First sale
- Oct 2007
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Humacyte went on to found or lead other companies.
Related companies · 7
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanksFinancial analysis and stock research platform.
Companies working in the same space as Humacyte.
Frequently asked questions
- What does Humacyte do?
- Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform. Its off-the-shelf vessels target vascular trauma, AV access, and peripheral artery disease (PAD), and have received FDA Regenerative Medicine Advanced Therapy designation.
- Who founded Humacyte?
- Humacyte was founded by Laura Niklason, MD, PhD.
- Who are Humacyte's investors?
- Humacyte's investors include First In Ventures, Fresenius Medical Care Ventures, Oberland Capital.
- How much funding has Humacyte raised?
- Humacyte has disclosed $274.8M raised across 3 of its 4 known rounds.
- Where is Humacyte headquartered?
- Humacyte is headquartered in Morrisville, US.